{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:35:53Z","timestamp":1790670953240,"version":"4.1.0"},"reference-count":58,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2019.2224","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:57:27Z","timestamp":1555102647000},"page":"e192224","source":"Crossref","is-referenced-by-count":85,"title":["Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes"],"prefix":"10.1001","volume":"2","author":[{"given":"Elvira","family":"D\u2019Andrea","sequence":"first","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer P.","family":"Hey","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cherie L.","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL) Biomarker Research Consortium, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"9","key":"zoi190103r1","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/ijcp.2009.63.issue-9","article-title":"The mechanism and mitigation of niacin-induced flushing.","volume":"63","author":"Kamanna","year":"2009","journal-title":"Int J Clin Pract"},{"issue":"24","key":"zoi190103r3","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi190103r4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients.","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi190103r5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","article-title":"2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"zoi190103r7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease: the Framingham study.","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"issue":"1","key":"zoi190103r8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies.","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"issue":"17","key":"zoi190103r9","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0002-9149(99)80761-9","article-title":"Distribution of lipids in 8500 men with coronary artery disease.","volume":"75","author":"Rubins","year":"1995","journal-title":"Am J Cardiol"},{"issue":"6","key":"zoi190103r10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi190103r11","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/jamainternmed.2013.6489","article-title":"Use of niacin in the United States and Canada.","volume":"173","author":"Jackevicius","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi190103r13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"zoi190103r14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.","volume":"61","author":"Lavigne","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"338","key":"zoi190103r15","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis.","author":"Briel","year":"2009","journal-title":"BMJ"},{"issue":"349","key":"zoi190103r16","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117?411 patients.","author":"Keene","year":"2014","journal-title":"BMJ"},{"issue":"339","key":"zoi190103r17","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","author":"Liberati","year":"2009","journal-title":"BMJ"},{"issue":"9753","key":"zoi190103r18","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170?000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"8","key":"zoi190103r19","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.2337\/dc08-0025","article-title":"Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study.","volume":"31","author":"Fox","year":"2008","journal-title":"Diabetes Care"},{"issue":"12","key":"zoi190103r20","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrcardio.2014.167","article-title":"Risk of coronary heart disease in patients with HIV infection.","volume":"11","author":"Zanni","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"9808","key":"zoi190103r21","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/S0140-6736(11)61125-2","article-title":"Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20?536 high-risk individuals: a randomised controlled trial.","volume":"378","author":"Bulbulia","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"zoi190103r22","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis.","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"7303","key":"zoi190103r23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: assessing the quality of controlled clinical trials.","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"issue":"3","key":"zoi190103r25","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials.","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"9","key":"zoi190103r26","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1002\/(ISSN)1097-0258","article-title":"What to add to nothing? use and avoidance of continuity corrections in meta-analysis of sparse data.","volume":"23","author":"Sweeting","year":"2004","journal-title":"Stat Med"},{"issue":"1","key":"zoi190103r27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events.","volume":"26","author":"Bradburn","year":"2007","journal-title":"Stat Med"},{"issue":"11","key":"zoi190103r28","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Quantifying heterogeneity in a meta-analysis.","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"4","key":"zoi190103r29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1177\/1536867X0800800403","article-title":"Meta-regression in Stata.","volume":"8","author":"Harbord","year":"2008","journal-title":"Stata J"},{"issue":"17","key":"zoi190103r30","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Improved tests for a random effects meta-regression with a single covariate.","volume":"22","author":"Knapp","year":"2003","journal-title":"Stat Med"},{"issue":"4","key":"zoi190103r32","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","author":"Coronary Drug Project","year":"1975","journal-title":"JAMA"},{"issue":"23","key":"zoi190103r33","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1001\/jama.1987.03390230069027","article-title":"Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.","volume":"257","author":"Blankenhorn","year":"1987","journal-title":"JAMA"},{"issue":"5","key":"zoi190103r34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.0954-6820.1988.tb15891.x","article-title":"Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.","volume":"223","author":"Carlson","year":"1988","journal-title":"Acta Med Scand"},{"issue":"19","key":"zoi190103r35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi190103r36","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1001\/jama.1990.03450230043027","article-title":"Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens.","volume":"264","author":"Kane","year":"1990","journal-title":"JAMA"},{"issue":"8931","key":"zoi190103r37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S0140-6736(94)90506-1","article-title":"Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients.","volume":"344","author":"Sacks","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"zoi190103r38","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1177\/000331979504600401","article-title":"Effect of lipid-lowering treatment on progression of atherosclerotic lesions: a duplex ultrasonographic investigation.","volume":"46","author":"Caruzzo","year":"1995","journal-title":"Angiology"},{"issue":"23","key":"zoi190103r39","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"zoi190103r40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"issue":"16","key":"zoi190103r41","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jacc.2008.03.003","article-title":"Lipid-altering efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.","volume":"51","author":"Guyton","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"zoi190103r42","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness.","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi190103r43","first-page":"1615","article-title":"Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.","volume":"122","author":"Sang","year":"2009","journal-title":"Chin Med J (Engl)"},{"issue":"22","key":"zoi190103r44","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1136\/heartjnl-2013-303926","article-title":"MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA Plaque study.","volume":"99","author":"Sibley","year":"2013","journal-title":"Heart"},{"issue":"2","key":"zoi190103r45","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2013.09.034","article-title":"The Effect of Lipid Modification on Peripheral Artery Disease After Endovascular Intervention Trial (ELIMIT).","volume":"231","author":"Brunner","year":"2013","journal-title":"Atherosclerosis"},{"issue":"2","key":"zoi190103r46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.amjmed.2016.07.038","article-title":"Role of niacin in current clinical practice: a systematic review.","volume":"130","author":"Garg","year":"2017","journal-title":"Am J Med"},{"key":"zoi190103r47","first-page":"CD009744","article-title":"Niacin for primary and secondary prevention of cardiovascular events.","volume":"6","author":"Schandelmaier","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"6A","key":"zoi190103r48","doi-asserted-by":"publisher","first-page":"22C","DOI":"10.1016\/j.amjcard.2006.11.018","article-title":"Safety considerations with niacin therapy.","volume":"99","author":"Guyton","year":"2007","journal-title":"Am J Cardiol"},{"issue":"7","key":"zoi190103r49","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1185\/030079907X199682","article-title":"Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients.","volume":"23","author":"Birjmohun","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"zoi190103r50","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1056\/NEJMc1311039","article-title":"Safety profile of extended-release niacin in the AIM-HIGH trial.","volume":"371","author":"Anderson","year":"2014","journal-title":"N Engl J Med"},{"issue":"355","key":"zoi190103r51","doi-asserted-by":"crossref","first-page":"i6286","DOI":"10.1136\/bmj.i6286","article-title":"Interpretation of surrogate endpoints in the era of the 21st Century Cures Act.","author":"Knopf","year":"2016","journal-title":"BMJ"},{"issue":"26","key":"zoi190103r52","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMp1506964","article-title":"The 21st Century Cures Act: will it take us back in time?","volume":"372","author":"Avorn","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi190103r53","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1001\/jama.2016.16437","article-title":"Approving a problematic muscular dystrophy drug: implications for FDA policy.","volume":"316","author":"Kesselheim","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"zoi190103r54","doi-asserted-by":"publisher","first-page":"e003121","DOI":"10.1161\/CIRCOUTCOMES.116.003121","article-title":"Success, failure, and transparency in biomarker-based drug development: a case study of cholesteryl ester transfer protein inhibitors.","volume":"10","author":"Hey","year":"2017","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"9912","key":"zoi190103r55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","article-title":"How to increase value and reduce waste when research priorities are set.","volume":"383","author":"Chalmers","year":"2014","journal-title":"Lancet"},{"issue":"9912","key":"zoi190103r56","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0140-6736(13)62227-8","article-title":"Increasing value and reducing waste in research design, conduct, and analysis.","volume":"383","author":"Ioannidis","year":"2014","journal-title":"Lancet"},{"issue":"6298","key":"zoi190103r57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1126\/science.aaf5101","article-title":"Biomedical research: countering imprecision in precision medicine.","volume":"353","author":"Hey","year":"2016","journal-title":"Science"},{"issue":"1","key":"zoi190103r58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cpt.v103.1","article-title":"Ethical challenges in biomarker-driven drug development.","volume":"103","author":"Hey","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"zoi190103r12","volume-title":"Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934","author":"Teva Pharmaceutical Industries Limited","year":"2016"},{"key":"zoi190103r24","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"Higgins","year":"2011"},{"key":"zoi190103r31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-1-4615-6866-7_34","volume-title":"Drugs Affecting Lipid Metabolism: Advances in Experimental Medicine and Biology","author":"Schoch","year":"1969"},{"key":"zoi190103r2","unstructured":"US Food and Drug Administration. NIASPAN: niacin extended-release tablets. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/020381s034lbl.pdf. Accessed March 7, 2019."},{"key":"zoi190103r6","unstructured":"US Centers for Medicare & Medicaid Services. Drug Coverage (Part D). https:\/\/www.medicare.gov\/drug-coverage-part-d. Accessed May 20, 2017."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/2\/4\/e192224\/17465353\/dandrea_2019_oi_190103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T20:57:43Z","timestamp":1555102663000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2019.2224"}},"subtitle":["A Systematic Review and Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,5]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2224","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]}}}